	US 11,701,410 B2
	Extracellular DNA as a therapeutic target in neurodegeneration
Dmitry Dmitrievich Genkin, Saint Petersburg (RU); Georgy Viktorovich Tets, Saint Petersburg (RU); and Viktor Veniaminovich Tets, Saint Petersburg (RU)
Assigned to CLS THERAPEUTICS LIMITED, Saint Peter Port (GG)
Appl. No. 15/576,611
Filed by CLS THERAPEUTICS LIMITED, Saint Peter Port (GG)
PCT Filed May 11, 2016, PCT No. PCT/RU2016/000284 § 371(c)(1), (2) Date Nov. 22, 2017, PCT Pub. No. WO2016/190780, PCT Pub. Date Dec. 1, 2016.
Claims priority of provisional application 62/165,255, filed on May 22, 2015.
Prior Publication US 2018/0360925 A1, Dec. 20, 2018
Int. Cl. A61K 38/46 (2006.01); A61K 47/61 (2017.01); A61K 9/00 (2006.01); A61P 25/28 (2006.01); A61P 25/18 (2006.01); A61P 25/16 (2006.01)

CPC A61K 38/465 (2013.01) [A61K 9/0019 (2013.01); A61K 9/0053 (2013.01); A61K 9/0085 (2013.01); A61K 47/61 (2017.08); A61P 25/16 (2018.01); A61P 25/18 (2018.01); A61P 25/28 (2018.01); C12Y 301/02021 (2013.01); C12Y 301/21001 (2013.01)]

30 Claims

1. A method for treating and/or inhibiting progression of primary neurodegeneration in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a DNase enzyme, wherein the neurodegeneration is associated with an increased level of extracellular DNA of prokaryotic origin in blood or cerebrospinal fluid or intestine of said patient, and wherein said therapeutically effective amount of the DNase enzyme is sufficient to decrease the average molecular weight of said extracellular DNA of prokaryotic origin.